Europe has Untapped Medical Innovation
The PharmaPhorum website noted that the ‘open innovation’ strategy is being pursued by all the big pharma companies – and now it’s simply a matter of who executes best on this approach. This is one of the boldest efforts in big pharma to create relationships with entrepreneurs, scientists and leading institutions and to help them advance their ideas. Working in ‘open innovation’ means collaborations with multiple partners, including rival companies, is a good way to operate. Johnson & Johnson has teamed up with GlaxoSmithKline and AstraZeneca and with the University of Cambridge, Imperial College, and University College London, to create the Apollo Therapeutics Fund.
Click here to read the full article.
